LOS ANGELES CAPITAL MANAGEMENT LLC

Position in ARDX — Ardelyx, Inc.

CIK 1177206 LOS ANGELES, CA

Position in ARDX

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$659,771

+$654,219 QoQ

Shares Held

129,367

+13855.4% QoQ

Ownership

0.052%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#84

of 250 holders

Holding Since

Jun 2020

11 quarters on record

Voting authority Sole 4% Shared 0% None 96%

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,466,927 across 167 Biotechnology names. ARDX ranks #48 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	729,635	$219,642,024
2	HALO	Halozyme Therapeutics, Inc.	1,938,035	$151,689,999
3	CAI	Caris Life Sciences, Inc.	3,958,531	$70,541,022
4	INCY	Incyte Corp	578,986	$65,633,852
5	VRTX	Vertex Pharmaceuticals Inc / Ma	130,802	$64,973,277
6	EXEL	Exelixis, Inc.	1,159,457	$63,086,055
7	REGN	Regeneron Pharmaceuticals, Inc.	98,585	$61,471,690
8	RPRX	Royalty Pharma plc	877,674	$49,211,181

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$659,771	129,367	+13855.4%	Shares	Sole	2026-08-13
2026-03-31	$5,552	927	-98.9%	Shares	Sole	2026-05-08
2025-12-31	$472,976	81,128	-69.4%	Shares	Sole	2026-02-11
2025-03-31	$1,302,809	265,338	-43.5%	Shares	Sole	2025-05-05
2024-12-31	$2,381,982	469,819	+175.5%	Shares	Sole	2025-02-04
2024-09-30	$1,175,048	170,544	+51.8%	Shares	Sole	2024-11-04
2024-06-30	$832,328	112,325	+120.1%	Shares	Sole	2024-08-05
2021-03-31	$337,845	51,034	+12.4%	Shares	Sole	2021-05-05
2020-12-31	$293,763	45,404	+8.6%	Shares	Sole	2021-03-10
2020-09-30	$219,418	41,794	+35.9%	Shares	Sole	2020-11-02
2020-06-30	$212,817	30,754	—	Shares	Sole	2020-08-05
No filing history on record for this holder in this stock.